Immunologic interference from sequential administration of live attenuated alphavirus vaccines - PubMed

Affiliations

• PMID: 9498442
• DOI: 10.1086/514240

Clinical Trial

Immunologic interference from sequential administration of live attenuated alphavirus vaccines

D J McClain et al. J Infect Dis. 1998 Mar.

Abstract

Two different human vaccine trials examined interference arising from sequential administration of vaccines against heterologous alphaviruses. The first trial indicated that persons previously vaccinated against Venezuelan equine encephalitis virus (VEEV) exhibited poor neutralizing antibody responses to a live attenuated chikungunya virus (CHIKV) vaccine (46% response rate). The second trial prospectively examined neutralizing antibody responses to live attenuated VEEV vaccine in persons previously inoculated with either CHIKV vaccine or placebo. Following seroconversion to CHIKV, CHIKV vaccine recipients' geometric mean titers (GMTs) to VEEV by 80% plaque-reduction neutralization titration never exceeded 10, compared with a peak GMT of 95 after VEEV vaccination for alphavirus-naive volunteers who initially received placebo (P < .003). ELISA antibody responses demonstrated cross-reactive IgG to VEEV after primary CHIKV immunization and then an anamnestic response upon subsequent VEEV vaccination. These data indicate that preexisting alphavirus immunity in humans interferes with subsequent neutralizing antibody response to a live attenuated, heterologous vaccine.

Similar articles

• Designing multivalent immunogens for alphavirus vaccine optimization.

  Read CM, Plante K, Rafael G, Rossi SL, Braun W, Weaver SC, Schein CH. Read CM, et al. Virology. 2021 Sep;561:117-124. doi: 10.1016/j.virol.2020.11.010. Epub 2021 Feb 5. Virology. 2021. PMID: 33823988 Free PMC article.

• Recombinant Isfahan Virus and Vesicular Stomatitis Virus Vaccine Vectors Provide Durable, Multivalent, Single-Dose Protection against Lethal Alphavirus Challenge.

  Nasar F, Matassov D, Seymour RL, Latham T, Gorchakov RV, Nowak RM, Leal G, Hamm S, Eldridge JH, Tesh RB, Clarke DK, Weaver SC. Nasar F, et al. J Virol. 2017 Mar 29;91(8):e01729-16. doi: 10.1128/JVI.01729-16. Print 2017 Apr 15. J Virol. 2017. PMID: 28148802 Free PMC article.

• Venezuelan and western equine encephalitis virus E1 liposome antigen nucleic acid complexes protect mice from lethal challenge with multiple alphaviruses.

  Rico AB, Phillips AT, Schountz T, Jarvis DL, Tjalkens RB, Powers AM, Olson KE. Rico AB, et al. Virology. 2016 Dec;499:30-39. doi: 10.1016/j.virol.2016.08.023. Epub 2016 Sep 12. Virology. 2016. PMID: 27632563 Free PMC article.

• Novel vaccination approaches against equine alphavirus encephalitides.

  Carossino M, Thiry E, de la Grandière A, Barrandeguy ME. Carossino M, et al. Vaccine. 2014 Jan 9;32(3):311-9. doi: 10.1016/j.vaccine.2013.11.071. Epub 2013 Dec 2. Vaccine. 2014. PMID: 24295803 Review.

• [The vaccines based on the replicon of the venezuelan equine encephalomyelitis virus against viral hemorrhagic fevers].

  Petrov AA, Plekhanova TM, Sidorova ON, Borisevich SV, Makhlay AA. Petrov AA, et al. Vopr Virusol. 2015;60(3):14-8. Vopr Virusol. 2015. PMID: 26281301 Review. Russian.

Cited by

• Chikungunya virus and prospects for a vaccine.

  Weaver SC, Osorio JE, Livengood JA, Chen R, Stinchcomb DT. Weaver SC, et al. Expert Rev Vaccines. 2012 Sep;11(9):1087-101. doi: 10.1586/erv.12.84. Expert Rev Vaccines. 2012. PMID: 23151166 Free PMC article. Review.

• A Bivalent Trans-Amplifying RNA Vaccine Candidate Induces Potent Chikungunya and Ross River Virus Specific Immune Responses.

  Schmidt C, Hastert FD, Gerbeth J, Beissert T, Sahin U, Perkovic M, Schnierle BS. Schmidt C, et al. Vaccines (Basel). 2022 Aug 23;10(9):1374. doi: 10.3390/vaccines10091374. Vaccines (Basel). 2022. PMID: 36146452 Free PMC article.

• Nanoparticle- and Microparticle-Based Vaccines against Orbiviruses of Veterinary Importance.

  Jiménez-Cabello L, Utrilla-Trigo S, Barreiro-Piñeiro N, Pose-Boirazian T, Martínez-Costas J, Marín-López A, Ortego J. Jiménez-Cabello L, et al. Vaccines (Basel). 2022 Jul 14;10(7):1124. doi: 10.3390/vaccines10071124. Vaccines (Basel). 2022. PMID: 35891288 Free PMC article. Review.

• DNA vaccine initiates replication of live attenuated chikungunya virus in vitro and elicits protective immune response in mice.

  Tretyakova I, Hearn J, Wang E, Weaver S, Pushko P. Tretyakova I, et al. J Infect Dis. 2014 Jun 15;209(12):1882-90. doi: 10.1093/infdis/jiu114. Epub 2014 Feb 28. J Infect Dis. 2014. PMID: 24585894 Free PMC article.

• Chikungunya Virus: Current Perspectives on a Reemerging Virus.

  Morrison CR, Plante KS, Heise MT. Morrison CR, et al. Microbiol Spectr. 2016 Jun;4(3):10.1128/microbiolspec.EI10-0017-2016. doi: 10.1128/microbiolspec.EI10-0017-2016. Microbiol Spectr. 2016. PMID: 27337473 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information